NCT04933747View on ClinicalTrials.gov

Study to Evaluate Safety and Tolerability of Iberdomide (CC-220) in Participants With Kidney Impairment Compared to Participants With Normal Kidney Function

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

August 12, 2021

Primary Completion Date

January 23, 2023

Study Completion Date

January 23, 2023

Conditions
Renal Insufficiency
Interventions
DRUG

Iberdomide

Administration of a single oral dose of 1mg iberdomide in participants

DRUG

Iberdomide

Administration of a single oral dose of 1mg iberdomide in participants on 2 occasions - once on a dialysis day and once on a non-dialysis day

Trial Locations (3)

32809

Local Institution - 001, Orlando

37920

Local Institution - 002, Knoxville

78215

Local Institution - 003, San Antonio

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY

NCT04933747 - Study to Evaluate Safety and Tolerability of Iberdomide (CC-220) in Participants With Kidney Impairment Compared to Participants With Normal Kidney Function | Biotech Hunter | Biotech Hunter